Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 1:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 5,134 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunodeficiency Virus, Human Clear all
Completed Phase 3 Interventional

A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen

NCT00135395
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir+ritonavir, Lopinavir+ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
52
States / cities
Hobson City, Alabama • Montgomery, Alabama • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2010 · Synced Oct 3, 2026, 1:19 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma

NCT00003595
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, CHOP regimen, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 3, 2026, 1:19 PM EDT
Not yet recruiting Phase 2 Interventional

Topical Curcumin for HPV Related Cervical Disease

NCT04266275
View directory record Official record
Conditions
Neoplasm Cervix
Interventions
Curcumin C3 Complex, Placebo
Drug
Lead sponsor
Lisa Flowers
Other
Eligibility
21 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 3, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3

NCT00000857
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin-12
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
16
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 3, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety of Griffithsin in a Carrageenan Gel in Healthy Women

NCT02875119
View directory record Official record
Conditions
HIV Infection
Interventions
Griffithsin Gel, Placebo Gel
Drug
Lead sponsor
Population Council
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 3, 2026, 1:19 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

HIV Pre-Exposure Prophylaxis Among an Unrecognized Sexual Minority Population

NCT05815030
View directory record Official record
Conditions
Pre-Exposure Prophylaxis
Interventions
video informational/educational intervention
Other
Lead sponsor
The Alternative Sexualities Health Research Alliance
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rio Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 3, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients

NCT00002098
View directory record Official record
Conditions
HIV Infections
Interventions
Lentinan, Didanosine
Drug
Lead sponsor
AJI Pharma USA
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Francisco, California • Maitland, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 3, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult Participants

NCT05184452
View directory record Official record
Conditions
HIV Infections
Interventions
PGDM1400LS (5mg/kg, IV), PGDM1400LS (20mg/kg, IV), PGDM1400LS (20mg/kg, SC), PGDM1400LS (40mg/kg, IV), PGDM1400LS (40mg/kg, SC), PGDM1400LS (1.4g, IV), PGDM1400LS (1.4g, SC), VRC07-523LS (20mg/kg, IV), VRC07-523LS (20mg/kg, SC), VRC07-523LS (1.4g, IV), VRC07-523LS (1.4g, SC), VRC07-523LS (40mg/kg, IV), PGT121.414.LS (20mg/kg, IV), PGT121.414.LS (20mg/kg, SC), PGT121.414.LS (1.4g, IV), PGT121.414.LS (1.4g, SC), PGT121.414.LS (40mg/kg, IV)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
5
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 3, 2026, 1:19 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Behavioral Economic Intervention to Improve HIV Behaviors in Sexual Minority Individuals

NCT06745947
View directory record Official record
Conditions
HIV Prevention
Interventions
EFT
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 34 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 3, 2026, 1:19 PM EDT
Completed Early Phase 1 Interventional Results available

A Mind Body Intervention to Reduce Symptoms Among People Aging With HIV

NCT03840525
View directory record Official record
Conditions
Mental Health, Physical Health
Interventions
The Qigong Intervention, Sham Qigong
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
50 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 3, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

NCT01209325
View directory record Official record
Conditions
Anal Cancer, Nonneoplastic Condition, Penile Cancer, Precancerous Condition
Interventions
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, laboratory biomarker analysis
Biological · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
13 Years to 26 Years · Male only
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
18
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 3, 2026, 1:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The HJ MILE HIV Prevention Intervention for Post-incarcerated Men

NCT01427543
View directory record Official record
Conditions
HIV, Risk Reduction Behavior
Interventions
MILE intervention
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 3, 2026, 1:19 PM EDT
Completed Not applicable Interventional Results available

Coaching for HCV and HIV

NCT04314414
View directory record Official record
Conditions
Hepatitis C, HIV Infections, Opioid-use Disorder
Interventions
PRC brief motivational interview intervention, Phone contact
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Oct 3, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers

NCT03441984
View directory record Official record
Conditions
HIV Infections
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 3, 2026, 1:19 PM EDT
Completed Phase 4 Interventional Results available

Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial

NCT00795717
View directory record Official record
Conditions
Cardiovascular Disease, HIV Infection
Interventions
Lovaza, Placebo
Drug
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 3, 2026, 1:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir

NCT00000898
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2000
U.S. locations
4
States / cities
San Francisco, California • Stanford, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 3, 2026, 1:19 PM EDT
Completed Phase 2 Interventional

A Study of a Combination of Four Drugs in Patients With Recent HIV Infection

NCT00002233
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Amprenavir, Lamivudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
15 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
New York, New York • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 3, 2026, 1:19 PM EDT
Completed Phase 2 Interventional

Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting

NCT00642499
View directory record Official record
Conditions
Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting, HIV Infections
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
36
States / cities
Bakersfield, California • Fresno, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Oct 3, 2026, 1:19 PM EDT
Completed No phase listed Observational

Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV Drugs

NCT00050063
View directory record Official record
Conditions
HIV Infections
Interventions
Therapeutic vaccinations from A5058s
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
14
States / cities
Torrance, California • Aurora, Colorado • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 3, 2026, 1:19 PM EDT
Completed Not applicable Interventional Results available

CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)

NCT01721226
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Intervention Arm (computer-based CARE+ Corrections tool), Educational video on opiate overdose prevention
Device · Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 3, 2026, 1:19 PM EDT
Completed No phase listed Observational

Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell

NCT05784415
View directory record Official record
Conditions
Leukemia, Leukemia, Lymphoblastic, Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, HIV Infections, HIV Associated Lymphoma, HIV Disease; Lymphoma
Interventions
Not listed
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 3, 2026, 1:19 PM EDT
Completed No phase listed Observational Results available

Quantifying Drug Adherence and Drug Exposure to Antiretroviral Therapy

NCT02012621
View directory record Official record
Conditions
HIV/AIDS
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
807 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 3, 2026, 1:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of 3T, a Sex-Positive HIV/STI Mobile App Intervention for Young Black Men Ages 14-19 Attracted to Men

NCT04135443
View directory record Official record
Conditions
HIV/AIDS and Infections, Sexual Behavior, Health Knowledge, Attitudes, Practice
Interventions
3T Tune in! Turn on! Turn up!, General Health Materials Website
Behavioral
Lead sponsor
ETR Associates
Other
Eligibility
14 Years to 19 Years · Male only
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Scotts Valley, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 3, 2026, 1:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epividian / AHF: Positive Pathways - HIV Retention in Care

NCT04147832
View directory record Official record
Conditions
HIV/AIDS
Interventions
Alert to provider
Other
Lead sponsor
Epividian
Industry
Eligibility
18 Years and older
Enrollment
10,521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 3, 2026, 1:19 PM EDT